On Sept. 25, 1998, the Genentech drug Herceptin (trastuzumab) was approved by the FDA Genentech drug Herceptin (trastuzumab) for treatment of patients with metastatic breast cancer whose tumors
overexpress the HER2 protein and who have received one or more chemotherapy regimens for
their metastatic disease.

.